Annual EBITDA
-$67.83 M
-$14.33 M-26.78%
December 31, 2023
Summary
- As of February 7, 2025, ATXS annual EBITDA is -$67.83 million, with the most recent change of -$14.33 million (-26.78%) on December 31, 2023.
- During the last 3 years, ATXS annual EBITDA has fallen by -$30.40 million (-81.20%).
- ATXS annual EBITDA is now -281.09% below its all-time high of -$17.80 million, reached on December 31, 2013.
Performance
ATXS EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly EBITDA
-$29.01 M
-$211.00 K-0.73%
September 30, 2024
Summary
- As of February 7, 2025, ATXS quarterly EBITDA is -$29.01 million, with the most recent change of -$211.00 thousand (-0.73%) on September 30, 2024.
- Over the past year, ATXS quarterly EBITDA has dropped by -$8.78 million (-43.38%).
- ATXS quarterly EBITDA is now -558.51% below its all-time high of -$4.41 million, reached on March 31, 2014.
Performance
ATXS Quarterly EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
TTM EBITDA
-$100.97 M
-$8.78 M-9.52%
September 30, 2024
Summary
- As of February 7, 2025, ATXS TTM EBITDA is -$100.97 million, with the most recent change of -$8.78 million (-9.52%) on September 30, 2024.
- Over the past year, ATXS TTM EBITDA has dropped by -$37.85 million (-59.96%).
- ATXS TTM EBITDA is now -2191.58% below its all-time high of -$4.41 million, reached on March 31, 2014.
Performance
ATXS TTM EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
EBITDA Formula
EBITDA = Net Income + Interest + Taxes + Depreciation + Amortization
ATXS EBITDA Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | -26.8% | -43.4% | -60.0% |
| 3 y3 years | -81.2% | -43.4% | -60.0% |
| 5 y5 years | -164.4% | -43.4% | -60.0% |
ATXS EBITDA Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3-year | -123.4% | at low | -205.2% | at low | -232.5% | at low |
| 5 y | 5-year | -150.4% | at low | -430.1% | at low | -272.7% | at low |
| alltime | all time | -281.1% | at low | -558.5% | at low | -2191.6% | at low |
Astria Therapeutics EBITDA History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sep 2024 | - | -$29.01 M(+0.7%) | -$100.97 M(+9.5%) |
| Jun 2024 | - | -$28.80 M(+19.3%) | -$92.19 M(+17.5%) |
| Mar 2024 | - | -$24.15 M(+27.1%) | -$78.49 M(+15.7%) |
| Dec 2023 | -$67.83 M(+26.8%) | -$19.00 M(-6.1%) | -$67.83 M(+7.5%) |
| Sep 2023 | - | -$20.24 M(+34.0%) | -$63.12 M(+14.2%) |
| Jun 2023 | - | -$15.10 M(+11.9%) | -$55.27 M(+7.1%) |
| Mar 2023 | - | -$13.49 M(-5.6%) | -$51.62 M(-3.5%) |
| Dec 2022 | -$53.50 M(+76.2%) | -$14.29 M(+15.4%) | -$53.50 M(+9.8%) |
| Sep 2022 | - | -$12.39 M(+8.2%) | -$48.72 M(+10.1%) |
| Jun 2022 | - | -$11.45 M(-25.5%) | -$44.23 M(+9.8%) |
| Mar 2022 | - | -$15.38 M(+61.7%) | -$40.27 M(+32.6%) |
| Dec 2021 | -$30.36 M(-18.9%) | -$9.51 M(+20.4%) | -$30.36 M(+1.8%) |
| Sep 2021 | - | -$7.90 M(+5.5%) | -$29.84 M(-9.0%) |
| Jun 2021 | - | -$7.49 M(+36.8%) | -$32.80 M(-5.9%) |
| Mar 2021 | - | -$5.47 M(-39.0%) | -$34.87 M(-6.9%) |
| Dec 2020 | -$37.44 M(+38.2%) | -$8.98 M(-17.4%) | -$37.44 M(+6.3%) |
| Sep 2020 | - | -$10.86 M(+13.7%) | -$35.20 M(+13.5%) |
| Jun 2020 | - | -$9.55 M(+18.8%) | -$31.02 M(+7.7%) |
| Mar 2020 | - | -$8.04 M(+19.2%) | -$28.80 M(+6.3%) |
| Dec 2019 | -$27.09 M | -$6.75 M(+1.0%) | -$27.09 M(+2.6%) |
| Sep 2019 | - | -$6.68 M(-8.8%) | -$26.39 M(+4.0%) |
| Jun 2019 | - | -$7.33 M(+15.6%) | -$25.37 M(+3.8%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Mar 2019 | - | -$6.33 M(+4.7%) | -$24.45 M(-4.7%) |
| Dec 2018 | -$25.65 M(-3.6%) | -$6.05 M(+6.9%) | -$25.65 M(+2.8%) |
| Sep 2018 | - | -$5.66 M(-11.6%) | -$24.95 M(-4.5%) |
| Jun 2018 | - | -$6.40 M(-15.0%) | -$26.13 M(-1.4%) |
| Mar 2018 | - | -$7.53 M(+40.8%) | -$26.49 M(-0.4%) |
| Dec 2017 | -$26.60 M(-23.6%) | -$5.35 M(-21.8%) | -$26.60 M(-10.6%) |
| Sep 2017 | - | -$6.84 M(+1.0%) | -$29.76 M(-4.1%) |
| Jun 2017 | - | -$6.77 M(-11.4%) | -$31.03 M(-7.0%) |
| Mar 2017 | - | -$7.64 M(-10.2%) | -$33.38 M(-4.1%) |
| Dec 2016 | -$34.83 M(+10.7%) | -$8.51 M(+4.8%) | -$34.83 M(-2.1%) |
| Sep 2016 | - | -$8.12 M(-11.0%) | -$35.59 M(-0.1%) |
| Jun 2016 | - | -$9.12 M(+0.4%) | -$35.64 M(+4.1%) |
| Mar 2016 | - | -$9.08 M(-2.0%) | -$34.23 M(+8.9%) |
| Dec 2015 | -$31.45 M(+46.8%) | -$9.27 M(+13.5%) | -$31.45 M(+12.3%) |
| Sep 2015 | - | -$8.17 M(+5.8%) | -$28.00 M(+8.8%) |
| Jun 2015 | - | -$7.72 M(+22.5%) | -$25.75 M(+10.4%) |
| Mar 2015 | - | -$6.30 M(+8.2%) | -$23.32 M(+8.8%) |
| Dec 2014 | -$21.43 M(+20.4%) | -$5.82 M(-1.5%) | -$21.43 M(+37.3%) |
| Sep 2014 | - | -$5.91 M(+11.6%) | -$15.61 M(+60.9%) |
| Jun 2014 | - | -$5.30 M(+20.2%) | -$9.70 M(+120.2%) |
| Mar 2014 | - | -$4.41 M | -$4.41 M |
| Dec 2013 | -$17.80 M | - | - |
FAQ
- What is Astria Therapeutics annual EBITDA?
- What is the all time high annual EBITDA for Astria Therapeutics?
- What is Astria Therapeutics annual EBITDA year-on-year change?
- What is Astria Therapeutics quarterly EBITDA?
- What is the all time high quarterly EBITDA for Astria Therapeutics?
- What is Astria Therapeutics quarterly EBITDA year-on-year change?
- What is Astria Therapeutics TTM EBITDA?
- What is the all time high TTM EBITDA for Astria Therapeutics?
- What is Astria Therapeutics TTM EBITDA year-on-year change?
What is Astria Therapeutics annual EBITDA?
The current annual EBITDA of ATXS is -$67.83 M
What is the all time high annual EBITDA for Astria Therapeutics?
Astria Therapeutics all-time high annual EBITDA is -$17.80 M
What is Astria Therapeutics annual EBITDA year-on-year change?
Over the past year, ATXS annual EBITDA has changed by -$14.33 M (-26.78%)
What is Astria Therapeutics quarterly EBITDA?
The current quarterly EBITDA of ATXS is -$29.01 M
What is the all time high quarterly EBITDA for Astria Therapeutics?
Astria Therapeutics all-time high quarterly EBITDA is -$4.41 M
What is Astria Therapeutics quarterly EBITDA year-on-year change?
Over the past year, ATXS quarterly EBITDA has changed by -$8.78 M (-43.38%)
What is Astria Therapeutics TTM EBITDA?
The current TTM EBITDA of ATXS is -$100.97 M
What is the all time high TTM EBITDA for Astria Therapeutics?
Astria Therapeutics all-time high TTM EBITDA is -$4.41 M
What is Astria Therapeutics TTM EBITDA year-on-year change?
Over the past year, ATXS TTM EBITDA has changed by -$37.85 M (-59.96%)